ALSO NOTED: AmerisourceBergen buys Bellco Health for $300M; UCB, Sanofi ship new allergy med Xycal;

> Pharma services company AmerisourceBergen completed its purchase of Bellco Health, a privately held drug distributor, for a cash price of about $190 million. Release

> UCB and Sanofi-Aventis announced that their new allergy drug Xyzal is now available in the U.S. Release

> Amylin, which got approval for its pen-injector form of the diabetes drug Symlin yesterday, wasn't so lucky with its request for key new uses of the drug. Release

> Abbott got an FDA waiver to sell a handheld blood analyzer to doctors' offices and other healthcare settings; previously, it could only be used in hospitals. Release

> The FDA gave Ranbaxy the go-ahead to make and sell an oral suspension of clarithromycin, the copycat form of Abbott Laboratories' Biaxin. Release

> Australia's CSL got the FDA nod for its flu vaccine and now plans to ship between mid-December and early February. Report

And Finally... Think research labs handling the world's most deadly germs are super careful? Sorry to burst your bubble, but these labs have lost shipments, and their workers have been repeatedly exposed to said deadly germs--and sometimes, the labs don't even report the mishaps. Report

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.